Common Cold Drug Pipeline Analysis Report 2024

According to the American Lung Association, adults get an average of 2-4 colds annually, mostly between September and May and children may suffer from an average of 6-8 colds each year. The treatment for the common cold includes over-the-counter medications to reduce the symptoms. Antibiotics are administered to fight infections caused by bacteria. Several clinical trials are underway to develop innovative treatments to improve and manage the condition. For instance, CM5321 is a potential treatment for the common cold and will be administered as a nasal spray.

Report Coverage

The Common Cold Drug Pipeline Report by Expert Market Research gives comprehensive insights into common cold drugs currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for the common cold. The report includes the analysis of over 100 pipeline drugs and 50+ companies. It will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from common cold.

The detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration and ongoing product development activities related to the common cold are covered.

Common Cold Drug Pipeline Outlook

Cold is a contagious upper respiratory infection which affects body areas like the throat, nose, sinuses, and trachea. There are several types of viruses which can cause a cold and the most common cold virus is the rhinovirus which causes up to 50% of common colds. The symptoms of the common cold appear in stages. Stage 1, called early stage, has symptoms like sneezing, cough, stuffy nose, and nasal congestion, among others. Stage 2 is called an active stage. It has symptoms like body aches, headache, fatigue along with runny eyes and nose among others. Stage 3 is called late stage, and some symptoms can persist.

There is no cure for a cold as most colds go away on their own in ten days. Since viruses cause colds, antibiotics do not work for colds. The treatment for the common cold includes over-the-counter medications to reduce symptoms, including, pain relievers such as acetaminophen and NSAIDs such as ibuprofen to relieve headaches and fever. Decongestants are also given such as pseudoephedrine, and antihistamines among others. Additionally, cough suppressants are also administered such as dextromethorphan and codeine to reduce coughing. Several pharma companies and research institutes are developing innovative treatments to manage the condition. For instance, G.ST Antivirals GmbH is currently conducting a phase II study for 2-DG-02 for the prevention of rhinovirus-associated illness. The increasing clinical trials and changing dynamics are impacting the clinical trial landscape significantly.

Common Cold – Drug Pipeline Therapeutic Assessment

This section of the report covers the analysis of common cold drugs based on several segmentations including:

By Phase

EMR’s pipeline assessment report covers 50+ drug analyses based on phase.

• Late-Stage Products (Phase 3 and Phase 4)
• Mid-Stage Products (Phase 2)
• Early-Stage Products (Phase I)
• Preclinical and Discovery Stage Products

By Drug Class

EMR’s pipeline assessment report covers 50+ drug analyses based on drug classes:

• Small Molecule
• Cell Therapy
• Peptides
• Polymer
• Small Molecule
• Gene Therapy

By Route of Administration

EMR’s pipeline assessment report covers 50+ drug analyses based on the route of administration.

• Oral
• Parenteral
• Others

Common Cold – Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase III covers a major share of the total clinical trials for the common cold.

Common Cold – Pipeline Assessment Segmentation, By Drug Classes

The drug molecules categories covered under common cold pipeline analysis include small molecule, cell therapy, peptides, polymer, small molecule, and gene therapy. According to NCBI, as of April 2021, there were 126 small-molecule drug trials with various stages for the potential treatment of COVID‐19 in at least 700 clinical trials. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for common cold.

Common Cold Clinical Trials Assessment – Competitive Dynamics

The EMR report for the common cold drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in common cold clinical trials:

• GlaxoSmithKline
• Laboratorios Silanes S.A. de C.V.
• Sandoz
• Enzymatica AB
• Xigo Health LLC
• Lallemand Pharma AG
• Bayer
• Eli Lilly and Company
• Boehringer Ingelheim
• Novartis
• McNeil AB
• PPC Pharmaceuticals
• Nycomed
• HALEON
• Others

Common Cold – Pipeline Drugs Profile

Drug: Paracetamol and Caffeine

The trial is designed to investigate if there is any improvement in performance based on cognitive function and mood assessment in patients suffering from the common cold while taking paracetamol and caffeine combination. The trial is sponsored by GlaxoSmithKline and is currently under phase IV.

Drug: Ibuprofen + Loratadine fixed dose

The objective of the study is to assess the safety of the drug combination of Ibuprofen/Loratadine versus Ibuprofen versus Loratadine as a monotherapy treatment for the common cold. The trial is sponsored by Laboratorios Silanes S.A. de C.V. and is currently under phase III.

Drug: Nasal Glucagon

Eli Lilly and Company is developing the drug and is currently under phase I. The study is being conducted to assess the safety of nasal glucagon in participants with a common cold.

Reasons To Buy This Report

The Common Cold Drug Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for common cold. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within common cold pipeline insights.

Key Questions Answered in the Common Cold – Pipeline Assessment Report

• What is the current landscape of common cold pipeline drugs?
• How many companies are developing common cold drugs?
• How many phase III and phase IV drugs are currently present in common cold pipeline drugs?
• Which companies/institutions are leading the common cold drug development?
• What is the efficacy and safety profile of common cold pipeline drugs?
• What are the opportunities and challenges present in the common cold drug pipeline landscape?
• Which company is conducting major trials for common cold drugs?
• What geographies are covered for common cold clinical trials?
• What are emerging trends in common cold clinical trials?

Related Reports

Global Zika Virus Therapeutics Market

North America Herpes Simplex Virus Treatment Market